Miller Anestesia

394. Henderson WA: Succinylcholine-induced cardiac

arrest in unsuspected Duchenne muscular dystro-

phy. Can Anaesth Soc J 31:444–446, 1984.

395. Goudsouzian NG, Ryan JF, Savarese JJ: The neuro-

muscular effects of pancuronium in infants and

children. Anesthesiology 41:95–98, 1974.

396. Fisher DM, O’Keeffe C, Stanski DR, et al: Pharma-

cokinetics and pharmacodynamics of

-tubocura-

rine in infants, children, and adults. Anesthesiology

57:203–208, 1982.

397. Fisher DM, Castagnoli K, Miller RD: Vecuronium

kinetics and dynamics in anesthetized infants and

children. Clin Pharmacol Ther 37:402–406, 1985.

398. Fisher DM, Miller RD: Neuromuscular effects of

vecuronium (ORG NC45) in infants and children

during N

O, halothane anesthesia. Anesthesiology

58:519–523, 1983.

399. Meretoja OA, Wirtavuori K, Neuvonen PJ: Age-

dependence of the dose-response curve of vecuro-

nium in pediatric patients during balanced

anesthesia. Anesth Analg 67:21–26, 1988.

400. Goudsouzian NG, Liu LM, Cote CJ, et al: Safety and

efficacy of atracurium in adolescents and children

anesthetized with halothane. Anesthesiology

59:459–462, 1983.

401. Meretoja OA, Taivainen T,Wirtavuori K: Cisatracu-

rium during halothane and balanced anaesthesia in

children. Paediatr Anaesth 6:373–378, 1996.

402. de Ruiter J, Crawford MW: Dose-response relation-

ship and infusion requirement of cisatracurium

besylate in infants and children during nitrous

oxide–narcotic anesthesia. Anesthesiology 94:790–

792, 2001.

403. Scheiber G,Ribeiro FC,Marichal A,et al: Intubating

conditions and onset of action after rocuronium,

vecuronium, and atracurium in young children.

Anesth Analg 83:320–324, 1996.

404. Taivainen T, Meretoja OA, Erkola O, et al: Rocuro-

nium in infants, children and adults during balan-

ced anaesthesia. Paediatr Anaesth 6:271–275, 1996.

405. Fisher DM, Cronnelly R, Miller RD, Sharma M: The

neuromuscular pharmacology of neostigmine in

infants and children. Anesthesiology 59:220–225,

1983.

406. Duvaldestin P, Saada J, Berger JL, et al: Pharmaco-

kinetics, pharmacodynamics, and dose-response

relationships of pancuronium in control and elderly

subjects. Anesthesiology 56:36–40, 1982.

407. Maddineni VR, Mirakhur RK, McCoy EP: Plasma

cholinesterase activity in elderly and young adults.

Br J Anaesth 72:497, 1994.

408. Maddineni VR, Mirakhur RK, McCoy EP, Sharpe

TD: Neuromuscular and haemodynamic effects of

mivacurium in elderly and young adult patients. Br

J Anaesth 73:608–612, 1994.

409. Soderberg M, Thomson D, White T: Respiration,

circulation and anaesthetic management in obesity.

Investigation before and after jejunoileal bypass.

Acta Anaesthesiol Scand 21:55–61, 1977.

410. Weinstein JA, Matteo RS, Ornstein E, et al: Pharma-

codynamics of vecuronium and atracurium in the

obese surgical patient. Anesth Analg 67:1149–1153,

1988.

411. Puhringer FK, Khuenl-Brady KS, Mitterschiffthaler

G: Rocuronium bromide: Time-course of action in

underweight, normal weight, overweight and obese

patients. Eur J Anaesthesiol Suppl 11:107–110,

1995.

412. Beemer GH, Bjorksten AR, Crankshaw DP: Effect

of body build on the clearance of atracurium: Impli-

cation for drug dosing.Anesth Analg 76:1296–1303,

1993.

413. Vandenbrom RH, Wierda JM, Agoston S: Pharma-

cokinetics and neuromuscular blocking effects of

atracurium besylate and two of its metabolites in

patients with normal and impaired renal function.

Clin Pharmacokinet 19:230–240, 1990.

414. Fahey MR, Morris RB, Miller RD, et al: Pharmaco-

kinetics of Org NC45 (norcuron) in patients with

and without renal failure. Br J Anaesth 53:1049–

1053, 1981.

415. Lynam DP, Cronnelly R, Castagnoli KP, et al: The

pharmacodynamics and pharmacokinetics of vecu-

ronium in patients anesthetized with isoflurane

with normal renal function or with renal failure.

Anesthesiology 69:227–231, 1988.

416. Somogyi AA, Shanks CA, Triggs EJ: The effect of

renal failure on the disposition and neuromuscular

blocking action of pancuronium bromide. Eur J

Clin Pharmacol 12:23–29, 1977.

417. Ward S, Neill EA: Pharmacokinetics of atracurium

in acute hepatic failure (with acute renal failure). Br

J Anaesth 55:1169–1172, 1983.

418. Bevan DR, Donati F, Gyasi H, Williams A: Vecuro-

nium in renal failure. Can Anaesth Soc J 31:491–

496, 1984.

419. Khuenl-Brady KS, Pomaroli A, Puhringer F, et al:

The use of rocuronium (ORG 9426) in patients with

chronic renal failure. Anaesthesia 48:873–875,

1993.

420. Hunter JM, Jones RS, Utting JE: Use of atracurium

in patients with no renal function. Br J Anaesth

54:1251–1258, 1982.

421. Hunter JM, Jones RS, Utting JE: Comparison of

vecuronium, atracurium and tubocurarine in

normal patients and in patients with no renal

function. Br J Anaesth 56:941–951, 1984.

422. Lebrault C, Duvaldestin P, Henzel D, et al: Pharma-

cokinetics and pharmacodynamics of vecuronium

in patients with cholestasis. Br J Anaesth 58:983–

987, 1986.

423. Nana A, Cardan E, Leitersdorfer T: Pancuronium

bromide. Its use in asthmatics and patients with

liver disease. Anaesthesia 27:154–158, 1972.

424. Westra P, Vermeer GA, de Lange AR, et al: Hepatic

and renal disposition of pancuronium and galla-

mine in patients with extrahepatic cholestasis. Br J

Anaesth 53:331–338, 1981.

425. Gyasi HK, Naguib M: Atracurium and severe

hepatic disease: A case report. Can Anaesth Soc J

32:161–164, 1985.

426. Servin FS, Lavaut E, Kleef U, Desmonts JM: Repea-

ted doses of rocuronium bromide administered to

cirrhotic and control patients receiving isoflurane.

A clinical and pharmacokinetic study. Anesthesio-

logy 84:1092–1100, 1996.

427. Bell CF, Hunter JM, Jones RS, Utting JE: Use of atra-

curium and vecuronium in patients with oesopha-

geal varices. Br J Anaesth 57:160–168, 1985.

428. Lawhead RG, Matsumi M, Peters KR, et al: Plasma

laudanosine levels in patients given atracurium

during liver transplantation. Anesth Analg 76:569–

573, 1993.

429. Ward JM, Rosen KM, Martyn JA: Acetylcholine

receptor subunit mRNA changes in burns are diffe-

rent from those seen after denervation: The 1993

Lindberg Award. J Burn Care Rehabil 14:595–601,

1993.

430. Martyn JA, Szyfelbein SK, Ali HH, et al: Increased

-tubocurarine requirement following major

thermal injury. Anesthesiology 52:352–355,

1980.

431. Edwards JP, Hatton PA, Little RA, et al: Increased

quantal release of acetylcholine at the neuromuscu-

lar junction following scald injury in the rat. Muscle

Nerve 22:1660–1666, 1999.

432. Tomera JF, Lilford K, Martyn JA: Diaphragm acetyl-

cholinesterase multimeric forms in mice in res-

ponse to burn trauma. J Burn Care Rehabil

14:406–419, 1993.

433. Martyn JA, White DA, Gronert GA, et al: Up-and-

down regulation of skeletal muscle acetylcholine

receptors. Effects on neuromuscular blockers.Anes-

thesiology 76:822–843, 1992.

434. Schaner PJ, Brown RL, Kirksey TD, et al: Succinyl-

choline-induced hyperkalemia in burned patients.

1. Anesth Analg 48:764–770, 1969.

435. Viby-Mogensen J, Hanel HK, Hansen E, Graae J:

Serum cholinesterase activity in burned patients.

II: Anaesthesia, suxamethonium and hyperka-

laemia. Acta Anaesthesiol Scand 19:169–179,

1975.

436. Murray MJ, Cowen J, DeBlock H, et al: Clinical

practice guidelines for sustained neuromuscular

blockade in the adult critically ill patient. Crit Care

Med 30:142–156, 2002.

437. Hansen-Flaschen JH, Brazinsky S, et al: Use of seda-

ting drugs and neuromuscular blocking agents in

patients requiring mechanical ventilation for respi-

ratory failure. A national survey. JAMA 266:2870–

2875, 1991.

438. Loper KA, Butler S, Nessly M, Wild L: Paralyzed

with pain: The need for education. Pain 37:315–316,

1989.

439. Pollard BJ: Muscle relaxants in critical care. Br J

Intensive Care 4:347–353, 1994.

440. Lacomis D, Petrella JT, Giuliani MJ: Causes of neu-

romuscular weakness in the intensive care unit: A

study of ninety-two patients. Muscle Nerve 21:610–

617, 1998.

441. Rudis MI, Guslits BJ, Peterson EL, et al: Economic

impact of prolonged motor weakness complicating

neuromuscular blockade in the intensive care unit.

Crit Care Med 24:1749–1756, 1996.

442. Lacomis D, Zochodne DW, Bird SJ: Critical illness

myopathy. Muscle Nerve 23:1785–1788, 2000.

443. Showalter CJ, Engel AG: Acute quadriplegic myopa-

thy: Analysis of myosin isoforms and evidence for

calpain-mediated proteolysis.Muscle Nerve 20:316–

322, 1997.

444. Shee CD: Risk factors for hydrocortisone myopathy in

acute severe asthma. Respir Med 84:229–233, 1990.

445. Hanson P, Dive A, Brucher JM, et al: Acute corticos-

teroid myopathy in intensive care patients. Muscle

Nerve 20:1371–1380, 1997.

446. Deconinck N, Van Parijs V, Beckers-Bleukx G, Van

den Bergh P: Critical illness myopathy unrelated to

corticosteroids or neuromuscular blocking agents.

Neuromuscul Disord 8:186–192, 1998.

447. DuBois DC, Almon RR: Disuse atrophy of skeletal

muscle is associated with an increase in number of

glucocorticoid receptors. Endocrinology 107:1649–

1651, 1980.

448. Hund E: Myopathy in critically ill patients. Crit

Care Med 27:2544–2547, 1999.

449. Neviere R, Mathieu D, Chagnon JL, et al: Skeletal

muscle microvascular blood flow and oxygen trans-

port in patients with severe sepsis.Am J Respir Crit

Care Med 153:191–195, 1996.

450. Tsukagoshi H, Morita T, Takahashi K, et al: Cecal

ligation and puncture peritonitis model shows

decreased nicotinic acetylcholine receptor numbers

in rat muscle: Immunopathologic mechanisms?

Anesthesiology 91:448–460, 1999.

451. De Letter MA, van Doorn PA, Savelkoul HF, et al:

Critical illness polyneuropathy and myopathy

(CIPNM): Evidence for local immune activation by

cytokine-expression in the muscle tissue. J Neuro-

immunol 106:206–213, 2000.

452. Tepper M, Rakic S, Haas JA, Woittiez AJ: Incidence

and onset of critical illness polyneuropathy in

patients with septic shock. Neth J Med 56:211–214,

2000.

453. van den Berghe G,Wouters P,Weekers F,et al: Inten-

sive insulin therapy in the critically ill patients. N

Engl J Med 345:1359–1367, 2001.

454. Zifko UA: Long-term outcome of critical illness

polyneuropathy. Muscle Nerve Suppl 9:S49–S52,

2000.

455. Dodson BA, Kelly BJ, Braswell LM, Cohen NH:

Changes in acetylcholine receptor number in

676

Farmacología y anestesia